In October 2025, a bankruptcy auction house in King of Prussia, Pennsylvania, sold 400 lots of laboratory equipment belonging to Venatorx Pharmaceuticals. Centrifuges, chromatography systems, biosafety cabinets — all going to the highest bidder. Just months earlier, Venatorx had announced Phase 3 results for cefepime-taniborbactam, a novel antibiotic that had proven clinically superior to meropenem, the current standard of care, in treating serious urinary tract infections. The drug worked. The company died anyway.
This is not an anomaly. It is the defining pattern of antibiotic development in the 21st century.
The Graveyard of Good Drugs
Venatorx is only the latest name on a growing list. Achaogen, which won FDA approval for plazomicin in 2018, filed for bankruptcy within a year — its drug generating just $800,000 in the quarter before collapse. Melinta Therapeutics, maker of Vabomere and Baxdela, went through bankruptcy in 2019. Aralez, Tetraphase, Paratek — all experienced severe financial distress despite bringing approved antibiotics to market.
Now add BiomX to the list. In July 2025, Nature Communications published their Phase 1b/2a results for BX004-A, a phage therapy for cystic fibrosis lung infections: a 500-fold reduction in bacterial burden versus placebo. Remarkable data. By December, the program was discontinued — not because the science failed, but because the company's $8.1 million cash balance could not support a redesigned Phase 2b trial. BiomX's Israeli subsidiary entered insolvency proceedings. In March 2026, the company announced an all-stock merger with Adaptive Phage Therapeutics — a survival play, not a victory.
Of twelve antibiotic-focused companies that went public in the past decade, only five remain active. The rest were acquired at fire-sale valuations, reverse-merged into other entities, or simply wound down.
The Stewardship Paradox
The root cause is a market failure so fundamental it borders on absurd. Antibiotics are the only class of drug where clinical success requires you to not use the product.
When a physician prescribes a new antibiotic, they are supposed to reserve it — to hold it back for the most resistant infections, the last-resort cases where nothing else works. This is good medicine. It is called antibiotic stewardship, and it is essential to slow the evolution of resistance. But it creates an economic nightmare. The better the drug is at killing resistant bacteria, the less it will be used, and the less revenue it will generate.
Cancer drugs generate billions because they are prescribed widely and used for long durations. A course of antibiotics lasts days. A breakthrough antibiotic might treat a few thousand patients per year — precisely because it should be reserved. No other therapeutic area punishes success this way.
The result is a market that cannot sustain the companies that serve it. New antibiotics typically generate less than $100 million per year in revenue — often far less. The average cost to develop one exceeds $1 billion. The math does not work. It has not worked for decades.
The Pipeline Is Collapsing
On March 10, 2026, the Access to Medicine Foundation released its AMR Benchmark — the most comprehensive assessment of the pharmaceutical industry's response to antimicrobial resistance. The headline finding was devastating.
The antibiotic pipeline among the 25 assessed companies dropped 35% in five years, from 92 projects in 2021 to just 60 in 2026. Small and medium enterprises, many operating on shoestring budgets, now account for roughly 25% of all pipeline projects — companies least equipped to survive the valley of death between clinical proof-of-concept and commercial viability.
The World Health Organization's 2025 pipeline report painted the same picture from a different angle: 90 agents in the global clinical pipeline, down from 97 in the prior assessment. Only 15 are considered truly innovative. Only five target the critical-priority pathogens — the carbapenem-resistant Gram-negatives that kill the most people.
"Without meaningful progress on policy reform, we are likely to see more biotechnology companies developing urgently needed antibiotics fail this year," warned Henry Skinner of the AMR Action Fund, a billion-dollar initiative created specifically to bridge this gap. "Not because the science falls short, but because the broken market offers no way to sustain success."
Cefepime-Taniborbactam: The Drug Nobody Owns
Perhaps no story illustrates the dysfunction more starkly than cefepime-taniborbactam.
In Phase 3 trials, it demonstrated clinical superiority over meropenem for complicated urinary tract infections — a bar that most antibiotics fail to clear, since regulators typically accept non-inferiority. The drug combined a well-known cephalosporin with a novel beta-lactamase inhibitor effective against metallo-beta-lactamases including NDM, the resistance mechanism that surged 461% in the United States between 2019 and 2023.
In February 2024, the FDA issued a Complete Response Letter citing manufacturing issues — not efficacy or safety concerns, but chemistry, manufacturing, and controls problems that Venatorx lacked the resources to resolve. More than two years later, no NDA resubmission has been filed. The only surviving asset from Venatorx's portfolio — ceftibuten-ledaborbactam, an oral antibiotic — was licensed to Basilea Pharmaceutica in August 2025 for up to $325 million in milestones.
Cefepime-taniborbactam itself? Orphaned. A clinically superior antibiotic targeting the fastest-growing resistance threat in the world, and no company is developing it.
The Access Gap
The economic failure does not only kill companies. It kills people — particularly in the parts of the world that need antibiotics most.
The AMR Benchmark found zero pediatric antibiotic formulations registered in 17 sub-Saharan African countries. Only five pediatric-specific development projects exist globally. Meanwhile, 95% of active pharmaceutical ingredients used in African nations are imported from China and India — creating supply chain vulnerabilities that compound the access problem.
This is the other face of the broken market. When developing antibiotics is economically irrational, companies do not invest in formulations for populations that cannot pay premium prices. Children in low-income countries are doubly abandoned: by the pathogens that disproportionately affect them, and by the markets that will not develop the drugs to treat them.
The WHO estimates that antimicrobial resistance directly killed 1.27 million people in 2019 and was associated with 4.95 million deaths. Updated projections suggest 1.91 million direct deaths annually by 2050, with 39 million cumulative over the next quarter century. The burden falls overwhelmingly on low- and middle-income countries.
Can Subscriptions Fix a Broken Market?
The most ambitious attempt to restructure antibiotic economics is about to go live.
On April 1, 2026, the United Kingdom will launch the world's first permanent antibiotic subscription model — a system where the government pays pharmaceutical companies a fixed annual fee for access to critical antibiotics, regardless of how many doses are actually dispensed. The idea is to decouple revenue from volume, eliminating the stewardship paradox.
The model evolved from a pilot launched in 2022, when the NHS contracted with Shionogi for cefiderocol and Pfizer for ceftazidime-avibactam at £10 million per year each. The expanded program tenders £1.9 billion over 16 years, with annual payments of up to £20 million per drug across four value bands determined by NICE assessment. Bidders must meet BSI Kitemark environmental manufacturing standards — a notable requirement linking antibiotic access to responsible production.
It is a bold experiment. But its limitations are significant. Even £20 million per year per drug falls far short of the revenue needed to incentivize de novo antibiotic development, which typically costs over $1 billion. The UK represents roughly 3% of the global pharmaceutical market. A subscription that works for one country does not solve the global incentive problem — it may simply attract drugs already developed for larger markets.
"The UK model is necessary but not sufficient," is the consensus among health economists. Without parallel initiatives in the US, Europe, and Japan, the subscription model risks becoming an island of rationality in a sea of market failure.
PASTEUR: The Bill That Cannot Pass
In the United States, the proposed solution is the PASTEUR Act — the Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act. Modeled on the same subscription concept, it would authorize $6 billion in government contracts paying $75–300 million per year for qualifying antibiotics.
It was first introduced in 2020. It was reintroduced in 2021, again in 2023, and most recently in February 2026 — its fourth iteration. Each version has attracted bipartisan support: 65 cosponsors and endorsement from 237 organizations, including every major infectious disease society, hospital association, and public health advocacy group in the country.
It has never received a floor vote.
The reasons are depressingly mundane. The bill competes for legislative bandwidth with higher-profile issues. Its $6 billion authorization — down from the original $11 billion — still triggers fiscal hawkishness in appropriations committees. And antibiotic resistance, despite killing more people than HIV/AIDS, lacks the political constituency to force action. There are no antibiotic resistance patient advocacy marches. The victims are dispersed, their deaths attributed to "complications" rather than resistance itself.
The latest version includes improvements: an objective scoring system for qualifying drugs, expanded stewardship provisions for outpatient settings, and grant programs for rural and safety-net hospitals. These are meaningful refinements. But refinement is irrelevant without enactment.
The Valley of Death
Between discovery and commercial viability lies what the industry calls the "valley of death" — the Phase 2 to Phase 3 gap where promising candidates go to die for lack of funding.
The AMR Action Fund was created in 2020 specifically to bridge this gap, with roughly $1 billion pooled from 24 pharmaceutical companies. It has made investments in several late-stage candidates. But a billion dollars sounds larger than it is: a single Phase 3 trial for a Gram-negative antibiotic can cost $100–200 million. The fund cannot rescue an entire field.
Public funders have tried to fill the void. BARDA (the Biomedical Advanced Research and Development Authority) has supported programs like Locus Biosciences' phage therapy pipeline with $93 million. CARB-X has funded 122 projects since its inception, with 14 reaching late-stage clinical development and 3 reaching market. ARPA-H awarded $27 million to Phare Bio for AI-driven antibiotic discovery. The Gates Foundation, Novo Nordisk Foundation, and Wellcome Trust committed $300 million through a partnership that launched the Gr-ADI consortium in January 2026 — $60 million across 18 projects in 17 countries.
These efforts are real and important. They are also insufficient. The total public and philanthropic investment in antibiotic development remains a fraction of what the private market invests in a single oncology drug. The asymmetry is not a gap — it is a chasm.
What Would Fix This
The economic diagnosis is clear and the prescriptions are known. They have been articulated by the O'Neill Review (2016), the WHO, the AMR Action Fund, the Duke-Margolis Center, and every serious analysis of antibiotic economics. What is needed:
Subscription-based pull incentives at scale. The UK model must be replicated and expanded. The US, EU, and Japan together represent over 60% of the global pharmaceutical market. Coordinated subscription programs across these markets, at the PASTEUR Act's proposed scale of $75–300 million per drug per year, would fundamentally change the return calculations for antibiotic developers.
Regulatory streamlining for antibiotics. The FDA's QIDP (Qualified Infectious Disease Product) designation already provides priority review and extended exclusivity. But these benefits do not help companies that cannot afford to reach the NDA stage. Adaptive trial designs, smaller pivotal studies for narrow-spectrum antibiotics, and expedited manufacturing reviews would reduce costs without compromising safety.
Pediatric and LMIC access mandates. Any pull incentive program should require developers to pursue pediatric formulations and ensure supply in low-income countries. The current system allows companies to optimize exclusively for wealthy adult populations — the 17 African countries with zero pediatric formulations are the result.
Diversified funding models. The Gr-ADI consortium and Phare Bio represent new approaches: philanthropic funding, open-source drug discovery, and nonprofit-commercial partnerships. These models bypass the broken venture capital pathway but need sustained investment to prove scalable.
The Cost of Waiting
Every year without meaningful reform, the pipeline shrinks. Every company that fails takes its institutional knowledge, its clinical data, and its compound libraries with it. Venatorx's cefepime-taniborbactam did not disappear because it stopped working — it disappeared because no one could afford to manufacture it. BiomX's phage therapy data is published in Nature Communications, waiting for a company healthy enough to advance it.
Meanwhile, NDM-producing superbugs surged 461% in the US. Candida auris spread to over 60 countries with 30–60% mortality. The WHO reports that 1 in 6 infections worldwide involves a resistant pathogen.
The UK subscription model launching on April 1 is a beginning — proof that governments can restructure the economics of essential medicines. But it is one country, offering up to £20 million per drug per year, in a crisis that demands coordinated global action at ten times that scale.
The science exists. The compounds exist. The clinical data exists. What does not exist — not yet, not at the scale required — is the economic architecture to turn those discoveries into medicines that reach the patients who need them.
We know how to fix this. We have known for a decade. The question is whether we will act before the pipeline empties entirely, or whether we will wait until the next pandemic-scale outbreak forces our hand — and discover that there is nothing left in the arsenal to deploy.
Key Sources: Access to Medicine Foundation AMR Benchmark 2026 (March 10, 2026); WHO Antibacterial Pipeline Report 2025; AMR Action Fund statement (March 2026); PASTEUR Act HR 7352, 119th Congress (February 2026); NHS England Antimicrobial Subscription Model Guidance; Lancet Commission on AMR (2022); EuroNews "Antimicrobial resistance is outpacing the industry's efforts" (March 11, 2026); CIDRAP PASTEUR Act coverage (2026); Nature Communications BX004-A Phase 1b/2a results (July 2025); BARDA/CARB-X/ARPA-H public funding data.